Incyte二季度业绩超预期并上调2026年销售指引，但核心增量部分来自已披露CMS和解

Earnings Call Insights: Incyte Corporation (INCY) Q2 2026
Management View
- "At the start of the year, we laid out a plan to move Incyte from reliance on a cornerstone product to a company with multiple growth drivers," William Meury (CEO & Director) said, adding that "6 months in, this transition is well underway" and that the company has "strengthened the core business, delivered key regulatory milestones, derisked and advanced our pipeline to late-stage development and added a novel Phase III hematology asset through business development."
- Meury said the company’s commercial performance was "above expectations" and emphasized diversification, stating the core business excluding Jakafi is "solidly on track to reach $3 billion to $4 billion in net sales by 2030" and that the company’s advantage is "our ability to launch and scale multiple products in parallel."
- On near-term catalysts, Meury highlighted "the approval and launch of Jakafi XR" and said Opzelura in moderate atopic dermatitis in Europe received a "positive CHMP opinion" with "final European Commission decision and signature expected in the third quarter."
- Pablo Cagnoni (President and Global Head of R&D) said, "All regulatory submissions supporting our 4 anticipated approvals for 2026 are now complete," and added, "many of our highest value catalysts, including data readout and regulatory decisions remain ahead."
- Cagnoni announced a pipeline change: "we decided to discontinue developing 058... Based on the totality of the data to date, we do not believe the molecule demonstrated the profile necessary to become a differentiated therapy."
- Suketu Upadhyay (Executive VP & CFO) said the quarter included "a onetime noncash benefit of $246 million" and guided to higher full-year expectations, stating, "We are raising our full year 2026 total net sales guidance to $5.130 billion to $5.260 billion."
Outlook
- Upadhyay updated full-year 2026 total net sales guidance to $5.130 billion to $5.260 billion, and said the company updated Opzelura full-year 2026 net sales guidance to $1.050 billion to $1.1 billion, reflecting "the incremental estimated impact of $300 million to $310 million of net sales related to the CMS settlement."
- Upadhyay said hematology and oncology guidance was "narrowing and raising" to $860 million to $890 million "based on strong performance in the first half of the year."
- Upadhyay raised expense guidance tied to the Vega acquisition, stating, "We are narrowing and raising our 2026 GAAP R&D and SG&A operating expense guidance to $4.915 billion to $4.995 billion" and that this included "an increase of approximately $1.270 billion related to the upfront payment for in-process research and development and associated transaction costs" plus "approximately $50 million" in ongoing Phase III development for latarcibart.
- Compared with the prior quarter, management moved from reaffirming full-year net sales guidance to raising guidance ranges, and tied the Opzelura change explicitly to the CMS settlement and gross-to-net improvement.
Financial Results
- Meury reported Q2 2026 total revenue of $1.67 billion and total net sales of $1.49 billion, stating that results included "a onetime noncash benefit from the CMS settlement" and that "excluding this benefit, total net sales increased 17%."
- Meury reported Jakafi Q2 sales of $817 million and said prescription demand for Jakafi increased 9%, while Jakafi XR generated $10 million in Q2 sales that "primarily consists of initial inventory build," with full-year XR sales expected to "approach $40 million to $50 million" and included within full-year Jakafi guidance.
- Meury reported Opzelura Q2 sales of $450 million, including $204 million of net product sales and "a onetime noncash benefit of $246 million" from the CMS settlement; he said the settlement "improves the economics of the business" and that prescription growth "should translate more efficiently into net sales growth going forward."
- Upadhyay reported Q2 GAAP expenses of $976 million and said that excluding a prior-year item, "total operating expenses grew 5%," while GAAP cost of goods was $105 million and the company expects COGS to be 8% to 9% for the full year.
- Upadhyay said Incyte ended the quarter with $4.5 billion in cash and cash equivalents, excluding the closing of the Vega acquisition in July.
Q&A
- Marc Frahm, TD Cowen: asked about remaining FDA questions for the 989 MF Phase III path; Pablo Cagnoni: said there are "2 paths" (standard SVR35/TSS50 vs. alternatives) and that discussions are aimed at incorporating hemoglobin and disease-modifying measures, adding, "We have initiated those conversations with FDA. They're going well. They've been constructive."
- Eric Schmidt, Cantor Fitzgerald: asked about BD capacity and R&D as a percent of sales; William Meury: said the company is "actively looking" for deals like Vega but is "comfortable being patient," and added, "We're not pursuing growth... at all costs" and "we're not solving right now for a fixed margin percentage."
- Tazeen Ahmad, BofA Securities: asked about Halozyme ENHANZE for 989; Pablo Cagnoni: said Incyte is executing the current subcutaneous plan and "adding another option now with the ENHANZE technology" to improve "flexibility" and potentially "patient experience."
- Faisal Khurshid, Jefferies: asked how to frame G12D (734) at ESMO and differentiation; Pablo Cagnoni: said Incyte will present "approximately 50 patients' worth of data" in first-line PDAC combo regimens and will also show CRC combination data; William Meury: said, "this will become about sequencing and matching the right drug with the biology" and called G12D "a real needle mover."
- Jay Olson, Oppenheimer: asked whether latarcibart could expand beyond VWD and be "the next Hemlibra"; David Gardner (Executive VP & Chief Strategy Officer): said, "there is potential to deliver a transformative Hemlibra-like opportunity" if the target product profile is delivered; William Meury added that adoption in severe bleeders "could be almost 10,000 people."
- Derek Archila, Wells Fargo: asked about the Niktimvo IPF opt-in framework and cost split; Pablo Cagnoni: said Syndax will disclose the data and that, if Incyte opts in, "there's nothing to prevent us from doing so," and that the agreement follows the same cost/economics sharing approach as other indications.
- Jason, Wolfe Research: asked about Jakafi XR conversion and reimbursement timing; Mohamed Issa (Executive VP & Head of U.S. Commercial): said reimbursement "has kicked in" and guided to exiting 2026 with XR at "somewhere between 3% to 5% of our demand" to support the $40 million to $50 million expectation.
- Matthew Phipps, William Blair: asked why 058 was discontinued and timing for next-gen; Pablo Cagnoni: said it was not only bioavailability and that next-gen programs are "reasonably close to an IND filing" with more data to be shared later in the year.
- Jessica Fye, JPMorgan: asked about Opzelura gross-to-net and povo vitiligo filing; William Meury: said gross-to-net moved from "the low 60s" to "the high 50s" after the settlement; Pablo Cagnoni: said vitiligo submission is planned "right after the approval in HS" with 2 years of safety follow-up, "going to go in early next year."
Sentiment Analysis
- Analysts were slightly positive, with multiple openings such as "Congrats" and questions focused on differentiation and execution risks (FDA endpoints for 989 MF, ESMO benchmarks for 734, and BD/expense discipline).
- Management tone was positive in prepared remarks and largely confident in Q&A, using language such as "remain confident in our outlook" (Executive VP & CFO Upadhyay) and "we're well on track" (Executive VP Issa), while also acknowledging select uncertainties (e.g., 989 MF endpoint discussions still in progress).
- Versus the prior quarter, Q2 added more specific financial updates (raised guidance ranges and quantified CMS settlement impacts) and included a more explicit program stop (058), while Q1 had a more prominent emphasis on new leadership appointments.
Quarter-over-Quarter Comparison
- Q2 emphasized a CMS settlement benefit and improved Opzelura economics, while Q1 focused on organic growth and reiterated baseline 2026 guidance ranges without settlement-driven revisions.
- Q2 added business development detail around the Vega transaction and latarcibart, while Q1 framed business development more as a strategic pillar and introduced multiple executive appointments.
- Analysts’ focus shifted from povorcitinib/Opzelura portfolio positioning and 734 safety updates in Q1 toward 989 MF regulatory design, ESMO expectations for 734/890, and the commercial mechanics of Jakafi XR conversion in Q2.
Risks and Concerns
- Meury cautioned that Opzelura requires active management, stating, "this is not a business we can put on autopilot," and added that the pricing and reimbursement environment remains "dynamic."
- Cagnoni highlighted portfolio attrition risk in practice through program discontinuation, stating the company stopped 058 because it lacked a differentiated profile, while also saying it "does not change our conviction" in JAK2 V617F as a target.
- Regulatory and clinical timing dependencies remained central, including pending FDA alignment on 989 MF endpoints and expected approvals for povorcitinib in HS and Monjuvi in first-line DLBCL.
Final Takeaway
Management framed Q2 as a step forward in diversifying beyond Jakafi, pairing higher 2026 net sales guidance and a CMS-related Opzelura economics improvement with continued launch execution (Jakafi XR), multiple near-term regulatory events (including Opzelura moderate AD in Europe), and late-stage pipeline momentum. At the same time, management underscored active pricing/access management for Opzelura, ongoing FDA discussions to shape 989’s MF registrational path, and a willingness to stop programs that do not meet differentiation thresholds, while integrating the Vega acquisition into both growth strategy and updated expense guidance.
Read the full Earnings Call Transcript